history of glp 1 drugs The evolution weight loss drugs: from dangers to GLP-1 blockbusters | BioKnow posted on the topic How Can GLP-1 Agonists Be
Description
In midbrain areas, such as the substantia nigra and ventral tegmental area, insulin upregulates dopamine transporter expression and reduces excitatory glutamatergic input, decreasing extracellular dopamine levels [90]
Expression and distribution of glucagon-like peptide-1 receptor mRNA, protein and binding in the male nonhuman primate (Macaca mulatta) brain
Co-administration leads to greater reductions in albuminuria and more pronounced initial declines in eGFR, indicative of reduced intraglomerular pressure [122,123]
The inhibitory effect of cinchonine on human platelet aggregation due to blockade of calcium influx
